Sartorius Stedim Biotech supplies equipment and consumables for biopharmaceutical manufacturing, with a strong focus on single-use technologies. Its portfolio includes bioreactors, filtration systems, fluid management and purification tools used in drug development and commercial production. The company is a key process partner for biotech and pharma firms that need scalable, contamination-controlled bioprocessing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 744.6 | — | 85.6 | — |
| Q2 2025 | 745 | — | 68.5 | — |
| Q4 2025 | 772.2 | — | 47.3 | — |
| Q1 2026 | 761.5 | 2.3% | 88.1 | 2.9% |
| Q2 2026 | 765.7 | 2.8% | 93 | 35.8% |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: Amundi S.A. (AMUN), Capgemini SE (CAP), Stellantis N.V. (STLAP), Bouygues SA (EN), Pernod Ricard SA (RI), Unibail-Rodamco-Westfield SE (URW)